Chetan Borkhataria

Dr. Chetan Borkhataria

Assistant Professor
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Heliyon
Verified
Journal Article
Open access
DSDhruv C. Sakhiya
Dhruv C. Sakhiya
CBChetan Borkhataria
Chetan Borkhataria
The objective of this review is, to discuss recent advancements in screening methods for co-formers, evaluation cum confirmation methods and co-crystallization with examples.

16 June 2023 in Results in Chemistry
Verified
Journal Article
Open access
KSKaushik Suhagiya
Kaushik Suhagiya
CBChetan Borkhataria
Chetan Borkhataria
SGSumit Gohil
Sumit Gohil
RMRavi A. Manek
Ravi A. Manek
KPKalpesh A. Patel
Kalpesh A. Patel
DPDhaval V. Patel
Dhaval V. Patel

2 June 2023 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
JMJaydeep Mehta
Jaydeep Mehta
CBChetan Borkhataria
Chetan Borkhataria
APAjay Patel
Ajay Patel
RMRavi Manek
Ravi Manek
NPNilesh Patel
Nilesh Patel
BMBhargvi Mistry
Bhargvi Mistry

25 March 2025 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MCMeet Chhatbar
Meet Chhatbar
CBChetan Borkhataria
Chetan Borkhataria
OPOm Patel
Om Patel
KRKomal Raichura
Komal Raichura
TPTrupesh Pethani
Trupesh Pethani
RMRavi Manek
Ravi Manek

11 November 2020 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
CBChetan Borkhataria
Chetan Borkhataria
DPDhavalkumar Patel
Dhavalkumar Patel
SBSwati Bhagora
Swati Bhagora
NPNilesh Patel
Nilesh Patel
KPKalpesh Patel
Kalpesh Patel
RMRavi Manek
Ravi Manek
Background: The present investigation aimed at preparing nanosuspension of irbesartan to improve its dissolution. Dissolution enhancement of irbesartan can improve the oral bioavailability. Here, it was also studied how media milling time can be reduced by subjecting irbesartan to prior homogenization and then media milling. Results: First, homogenization of irbesartan was carried out in the presence of poloxamer 407 at 6000 rpm for 2 h. Final nanosuspension preparation was done by media milling with zirconium dioxide beads. Here, the amount of poloxamer 407 and zirconium dioxide beads was studied as statistical independent variables. Response surface plot analysis and desirability function were applied to the selected optimized batch. The prepared batches were subjected to evaluation for zeta potential value, mean particle size, PDI, dissolution study, and stability study. Target particle size was less than 500 nm, and in vitro dissolution in 10 min was more than 80%. Zeta potential value was ~ 27 mV for optimized nanosuspension. Desirability of 0.941 was achieved. Checkpoint batch was prepared and evaluated to confirm the validity of mathematical model. Accelerated stability study was performed on the optimized batch at 40 ± 2 °C/75 ± 5% RH for 6 months. Conclusion: The results confirmed the stability of formulation at accelerated stability conditions. Using presuspension prepared by homogenization, media milling time primarily reduced from 24–28 h to 18 h. Future perspective is to study other factors in combination method in discrete.

19 April 2025 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
NSNandlal Savaliya
Nandlal Savaliya
CBChetan Borkhataria
Chetan Borkhataria
KDKiran Dudhat
Kiran Dudhat
SSSunny Shah
Sunny Shah
TPTrupesh Pethani
Trupesh Pethani
MDMori Dhaval
Mori Dhaval